Author: Piccioni, Andrea; Santoro, Michele Cosimo; de Cunzo, Tommaso; Tullo, Gianluca; Cicchinelli, Sara; Saviano, Angela; Valletta, Federico; Pascale, Marco Maria; Candelli, Marcello; Covino, Marcello; Franceschi, Francesco
Title: Presepsin as Early Marker of Sepsis in Emergency Department: A Narrative Review Cord-id: lg3ezf4i Document date: 2021_7_29
ID: lg3ezf4i
Snippet: The diagnosis and treatment of sepsis have always been a challenge for the physician, especially in critical care setting such as emergency department (ED), and currently sepsis remains one of the major causes of mortality. Although the traditional definition of sepsis based on systemic inflammatory response syndrome (SIRS) criteria changed in 2016, replaced by the new criteria of SEPSIS-3 based on organ failure evaluation, early identification and consequent early appropriated therapy remain th
Document: The diagnosis and treatment of sepsis have always been a challenge for the physician, especially in critical care setting such as emergency department (ED), and currently sepsis remains one of the major causes of mortality. Although the traditional definition of sepsis based on systemic inflammatory response syndrome (SIRS) criteria changed in 2016, replaced by the new criteria of SEPSIS-3 based on organ failure evaluation, early identification and consequent early appropriated therapy remain the primary goal of sepsis treatment. Unfortunately, currently there is a lack of a foolproof system for making early sepsis diagnosis because conventional diagnostic tools like cultures take a long time and are often burdened with false negatives, while molecular techniques require specific equipment and have high costs. In this context, biomarkers, such as C-Reactive Protein (CRP) and Procalcitonin (PCT), are very useful tools to distinguish between normal and pathological conditions, graduate the disease severity, guide treatment, monitor therapeutic responses and predict prognosis. Among the new emerging biomarkers of sepsis, Presepsin (P-SEP) appears to be the most promising. Several studies have shown that P-SEP plasma levels increase during bacterial sepsis and decline in response to appropriate therapy, with sensitivity and specificity values comparable to those of PCT. In neonatal sepsis, P-SEP compared to PCT has been shown to be more effective in diagnosing and guiding therapy. Since in sepsis the P-SEP plasma levels increase before those of PCT and since the current methods available allow measurement of P-SEP plasma levels within 17 min, P-SEP appears a sepsis biomarker particularly suited to the emergency department and critical care.
Search related documents:
Co phrase search for related documents- accurate rapid and acute disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- accurate rapid and low accuracy: 1, 2, 3, 4
- accurate rapid and lps lipopolysaccharide: 1
- accurate rapid method and acute disease: 1, 2
- accurate rapid method and lps lipopolysaccharide: 1
- accurately effectively and acute disease: 1
- acute acute and lps lipopolysaccharide: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- acute acute and macrophage monocyte: 1, 2, 3, 4, 5
- acute disease and low accuracy: 1, 2, 3
- acute disease and lps lipopolysaccharide: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute disease and macrophage monocyte: 1, 2, 3, 4, 5
- lps lipopolysaccharide and macrophage monocyte: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date